Walbenazyna: interakcje

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (etykieta leku Amiodaron, Ostrzeżenia i środki ostrożności)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (etykieta leku Cyprofloksacyna, Ostrzeżenia i środki ostrożności)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Taking tetrabenazine or valbenazine [see Drug Interactions ( 7.6 )] . (etykieta leku Deutetrabenazyna, Przeciwwskazania)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (etykieta leku Dofetylid, Ostrzeżenia)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (etykieta leku Emtrycytabina + rylpiwiryna + tenofowir, Ostrzeżenia i środki ostrożności)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (etykieta leku Flukonazol, Przeciwwskazania)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (etykieta leku Fosfomycyna, Interakcje z innymi lekami)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (etykieta leku Foskarnet, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (etykieta leku Hydroksychlorochina, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etykieta leku Iwabradyna, Ostrzeżenia i środki ostrożności)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (etykieta leku Lewofloksacyna, Ostrzeżenia i środki ostrożności)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (etykieta leku Mirtazapina, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (etykieta leku Oksaliplatyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (etykieta leku Pitolisant, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (etykieta leku Propafenon, Ostrzeżenia i środki ostrożności)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (etykieta leku Repaglinid, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Avoid the concomitant use of drugs known to prolong the QTc interval. (etykieta leku Sertralina, Interakcje z innymi lekami)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

• Taking deutetrabenazine or valbenazine [see Drug Interactions ( 7.7 )] . (etykieta leku Tetrabenazyna, Przeciwwskazania)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Use of strong CYP3A4 inducers with INGREZZA or INGREZZA SPRINKLE Concomitant use is not recommended. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Dose adjustments due to drug interactions ( 2.4 , 7.1 ): Factors Dose Adjustments for INGREZZA and INGREZZA SPRINKLE Use of MAOIs with INGREZZA or INGREZZA SPRINKLE Avoid concomitant use with MAOIs. (etykieta leku Walbenazyna, Interakcje z innymi lekami)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (etykieta leku Vepdegestrant, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Drug Interactions Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with β-blocking agents. (etykieta leku Acebutolol, Interakcje z innymi lekami)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (etykieta leku Arformoterol, Interakcje z innymi lekami)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. (etykieta leku Atenolol, Interakcje z innymi lekami)

Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e.g., reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. (etykieta leku Atenolol + chlortalidon, Interakcje z innymi lekami)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents. (etykieta leku Betaksolol, Interakcje z innymi lekami)

Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of BISOPROLOL FUMARATE may produce excessive reduction of sympathetic activity. (etykieta leku Bisoprolol, Interakcje z innymi lekami)

Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored because the added beta-adrenergic blocking action of bisoprolol fumarate may produce excessive reduction of sympathetic activity. (etykieta leku Bisoprolol + hydrochlorotiazyd, Interakcje z innymi lekami)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Catecholamine-depleting Drugs Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (etykieta leku Brymonidyna + tymolol, Interakcje z innymi lekami)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (etykieta leku Buprenorfina, Ostrzeżenia i środki ostrożności)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (etykieta leku Buprenorfina + nalokson, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Avoid use of Citalopram Capsules in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure and patients taking other drugs that prolong the QTc interval. (etykieta leku Cytalopram, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Desfluran, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Digoxin Clinical Implication: Concomitant use of INGREZZA or INGREZZA SPRINKLE with digoxin increased digoxin levels because of inhibition of intestinal P-glycoprotein (P-gp) [see Clinical Pharmacology ( 12.3 )] . (etykieta leku Walbenazyna, Interakcje z innymi lekami)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (etykieta leku Dorzolamid + tymolol, Interakcje z innymi lekami)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

…cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (etykieta leku Droperydol, Ostrzeżenia)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (etykieta leku Erybulina, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

…prolonged QT interval, 3) treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte… (etykieta leku Fentanyl, Ostrzeżenia i środki ostrożności)

…that Antagonize the Pressor Effect The increasing blood pressure effect of BIORPHEN is decreased in patients receiving: α-adrenergic antagonists Phosphodiesterase Type 5 inhibitors Mixed α- and β-receptor antagonists Calcium channel blockers, such as nifedipine Benzodiazepines ACE inhibitors Centrally acting sympatholytic agents, such as reserpine, guanfacine (etykieta leku Fenylefryna, Interakcje z innymi lekami)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

…Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (etykieta leku Formoterol, Interakcje z innymi lekami)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. (etykieta leku Glimepiryd, Interakcje z innymi lekami)

The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. (etykieta leku Glipizyd, Interakcje z innymi lekami)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Goserelina, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

This observation should be considered in making clinical decisions regarding patient monitoring when prescribing HYSINGLA ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. (etykieta leku Hydrokodon, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine and reserpine Intervention: Increased frequency of glucose monitoring may be required when Insulin Aspart is concomitantly administered with these drugs. (etykieta leku Insulina aspart, Interakcje z innymi lekami)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine Intervention: Increased frequency of glucose monitoring may be required when Insulin Degludec is co-administered with these drugs. (etykieta leku Insulina degludec, Interakcje z innymi lekami)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine Intervention: Increased frequency of glucose monitoring may be required when LEVEMIR is co-administered with these drugs. (etykieta leku Insulina detemir, Interakcje z innymi lekami)

Drugs that May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine. (etykieta leku Insulina glargine, Interakcje z innymi lekami)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: Beta-blockers, clonidine, guanethidine, and reserpine. (etykieta leku Insulina lispro, Interakcje z innymi lekami)

Mechanism and Clinical Effect(s) Concomitant use of pentamidine with AFREZZA may cause hypoglycemia, which may sometimes be followed by hyperglycemia Beta-blockers, Clonidine, Guanethidine, and Reserpine Prevention or Management Monitor blood glucose more frequently and modify AFREZZA dosage, as clinically indicated, when used concomitantly with these drugs. (etykieta leku Insulina ludzka krótko działająca, Interakcje z innymi lekami)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Izofluran, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (etykieta leku Karwedilol, Interakcje z innymi lekami)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Postganglionic Blocking Agents Agents such as reserpine potentiate cocaine-induced sympathetic stimulation; concurrent use may increase the risk of hypertension and cardiac arrhythmias that may be life-threatening. (etykieta leku Kokaina, Interakcje z innymi lekami)

TYKERB may prolong the QT interval in some patients. (etykieta leku Lapatynib, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Leuprorelina, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (etykieta leku Lofeksydyna, Ostrzeżenia i środki ostrożności)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (etykieta leku Meflochina, Interakcje z innymi lekami)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Catecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. (etykieta leku Metoprolol, Interakcje z innymi lekami)

Drug Interactions with Metoprolol Catecholamine Depleting Drugs: The concomitant use of catecholamine-depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) with beta adrenergic blockers may have an additive affect and increase the risk of hypotension or bradycardia CYP2D6 Inhibitors: Drugs that are strong inhibitors of CYP2D6 such as quinidine,… (etykieta leku Metoprolol + hydrochlorotiazyd, Interakcje z innymi lekami)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (etykieta leku Metronidazol, Interakcje z innymi lekami)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (etykieta leku Moksyfloksacyna, Ostrzeżenia i środki ostrożności)

Catecholamine-depleting drugs (e.g., reserpine) - additive effect; monitor closely for evidence of hypotension and/or excessive bradycardia (e.g., vertigo, syncope, postural hypotension). (etykieta leku Nadolol, Interakcje z innymi lekami)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: beta-blockers, clonidine, guanethidine, and reserpine Intervention: Increased frequency of glucose monitoring may be required when nateglinide is coadministered with these drugs. (etykieta leku Nateglinid, Interakcje z innymi lekami)

Reserpine or clonidine may produce excessive reduction of sympathetic activity. (etykieta leku Nebiwolol, Interakcje z innymi lekami)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etykieta leku Pasyreotyd, Interakcje z innymi lekami)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Drug Interactions Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. (etykieta leku Pindolol, Interakcje z innymi lekami)

The signs of hypoglycemia may be reduced or absent in patients taking sympatholytic drugs such as beta-blockers, clonidine, guanethidine, and reserpine. (etykieta leku Pioglitazon + glimepiryd, Interakcje z innymi lekami)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (etykieta leku Ponesimod, Interakcje z innymi lekami)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (etykieta leku Prymachina, Interakcje z innymi lekami)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (etykieta leku Rokuronium, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Neuroleptic Malignant Syndrome (NMS ) A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with drugs that reduce dopaminergic transmission. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (etykieta leku Rylpiwiryna, Ostrzeżenia i środki ostrożności)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Sewofluran, Ostrzeżenia)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etykieta leku Sorafenib, Ostrzeżenia i środki ostrożności)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (etykieta leku Sotalol, Interakcje z innymi lekami)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etykieta leku Sunitynib, Interakcje z innymi lekami)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

For patients who are CYP2D6 poor metabolizers or are taking a strong CYP2D6 inhibitor, dose reduction may be necessary. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Tryptorelina, Ostrzeżenia i środki ostrożności)

Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. (etykieta leku Tymolol, Interakcje z innymi lekami)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

In patients taking a strong CYP2D6 or CYP3A4 inhibitor, or who are CYP2D6 poor metabolizers, INGREZZA and INGREZZA SPRINKLE concentrations may be higher and QT prolongation clinically significant [see Clinical Pharmacology ( 12.2 )] . (etykieta leku Walbenazyna, Ostrzeżenia i środki ostrożności)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etykieta leku Zasadowy cytrynian bizmutu + metronidazol + tetracyklina, Ostrzeżenia i środki ostrożności)

Examples of acidifying agents include gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid hydrochloride, ascorbic acid) and urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts). (etykieta leku Deksamfetamina, Interakcje z innymi lekami)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (etykieta leku Efedryna, Interakcje z innymi lekami)

Phenoxybenzamine hydrochloride blocks hyperthermia production by levarterenol, and blocks hypothermia production by reserpine. (etykieta leku Fenoksybenzamina, Interakcje z innymi lekami)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)